Benitec, Children's Cancer Institute Australia to Co-Develop Lung Cancer Rx
October 01, 2009
Benitec, Children's Cancer Institute Australia to Co-Develop Lung Cancer Rx
The company said it has signed a term sheet for an option to license patent applications related to knocking down beta III-tubulin using RNAi, an approach that has been shown to sensitize cancer cells to chemotherapy.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Benitec, Collaborators Report on Expressed RNAi Treatment for Heart Graft Rejection
August 2, 2012 / Gene Silencing News - Benitec Aims for Three Clinical Programs, Industry Partnership in 2013
April 5, 2012 / Gene Silencing News - Benitec Adds Rare Form of Muscular Dystrophy to Pipeline, Seeks Collaboration for Pain Program
November 3, 2011 / Gene Silencing News - Benitec, Biomics Advance HBV Partnership
February 24, 2011 / Gene Silencing News - Tacere Considers Sale of Company as Pfizer Exercises Option to HCV Program
February 11, 2010 / Gene Silencing News